In last trading session, Rocket Pharmaceuticals Inc (NASDAQ:RCKT) saw 3.26 million shares changing hands with its beta currently measuring 0.98. Company’s recent per share price level of $7.14 trading at $0.17 or 2.44% at ring of the bell on the day assigns it a market valuation of $761.34M. That closing price of RCKT’s stock is at a discount of -277.87% from its 52-week high price of $26.98 and is indicating a premium of 36.27% from its 52-week low price of $4.55. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 4.35 million shares which gives us an average trading volume of 2.30 million if we extend that period to 3-months.
For Rocket Pharmaceuticals Inc (RCKT), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.12. Splitting up the data highlights that, out of 8 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 1 suggested the stock as a Hold whereas 7 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.58 in the current quarter.
Rocket Pharmaceuticals Inc (NASDAQ:RCKT) trade information
Upright in the green during last session for gaining 2.44%, in the last five days RCKT remained trading in the green while hitting it’s week-highest on Wednesday, 04/23/25 when the stock touched $7.14 price level, adding 4.03% to its value on the day. Rocket Pharmaceuticals Inc’s shares saw a change of -43.20% in year-to-date performance and have moved 9.34% in past 5-day. Rocket Pharmaceuticals Inc (NASDAQ:RCKT) showed a performance of -18.21% in past 30-days. Number of shares sold short was 12.44 million shares which calculate 6.83 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 35.5 to the stock, which implies a rise of 79.89% to its current value. Analysts have been projecting 32 as a low price target for the stock while placing it at a high target of 39. It follows that stock’s current price would drop -348.18% in reaching the projected high whereas dropping to the targeted low would mean a loss of -348.18% for stock’s current value.
10 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 800k for the same. And 10 analysts are in estimates of company making revenue of 1M in the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of -11.60% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 10.35% while estimates for its earnings growth in next 5 years are of 67.53%.
Rocket Pharmaceuticals Inc (NASDAQ:RCKT)’s Major holders
Insiders are in possession of 3.02% of company’s total shares while institution are holding 107.57 percent of that, with stock having share float percentage of 110.91%. Investors also watch the number of corporate investors in a company very closely, which is 107.57% institutions for Rocket Pharmaceuticals Inc that are currently holding shares of the company. RTW INVESTMENTS, LP is the top institutional holder at RCKT for having 17.69 million shares of worth $380.82 million. And as of 2024-06-30, it was holding 18.8677 of the company’s outstanding shares.
The second largest institutional holder is WELLINGTON MANAGEMENT GROUP LLP, which was holding about 9.16 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.7665 of outstanding shares, having a total worth of $197.12 million.
On the other hand, VANGUARD SPECIALIZED FUNDS-Vanguard Health Care Fund and VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Jan 31, 2025 , the former fund manager was holding 7.6 shares of worth $54.25 million or 7.13% of the total outstanding shares. The later fund manager was in possession of 2.62 shares on Dec 31, 2024 , making its stake of worth around $18.72 million in the company or a holder of 2.46% of company’s stock.
